Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Leuprorelin (Lucrin Depot) in Patients With Advanced Prostate Cancer (PCa) in Russia

1. Histologically confirmed advanced PCa meeting the following criteria: 1. Any Tumor, Node 1, Metastasis 0 2. Any Tumor, Node 0, Metastasis 1 \[according to Tumor Node Metastasis classification 2009\] 2. Participants planned for administration of leuprorelin 3. World Health Organization status 0-1 4. Life expectancy at least 2 years

1. Contraindications to administration of leuprorelin: 1. Hypersensitivity to Leuprorelin similar products of protein origin or any of the excipients in drug product composition 2. Surgical castration 2. Hormone-refractory PCa 3. Presence of another malignant tumor (except skin cancer) 4. Previous administration of hormone therapy with gonadotropin-releasing hormone agonists or antiandrogens 5. Previous administration of radiotherapy or chemotherapy course within 1 month 6. Testosterone level less than or equal to 50 ng/dl (less than or equal to 1.7 mmol/l) at time of inclusion 7. Extremely high level of PSA (greater than or equal to 1000 ng/ml) 8. Other severe diseases in stage of decompensation 9. Other contraindications, that make the participant's participation impossible (by investigator judgment) 10. Previous enrollment in the present program